Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine

Guy, Bruno; Chanthavanich, Pornthep; Gimenez, Sophie; Sirivichayakul, Chukiat; Sabchareon, Arunee; Begue, Sarah; Yoksan, Sutee; Luxemburger, Christine; Lang, Jean

doi:10.1016/j.vaccine.2004.03.042

Cited by 55 publications

(39 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The MOI for each DENV was adjusted to produce a baseline level of Ϸ3 log 10 FFU/ml in the supernatant of K562 cells 4 days after infection. For flow cytometry, cells were infected with DENV in the presence of various concentrations of test antibody or DENV sero-negative human IgG as a control essentially as described (34). Briefly, Ϸ4 ϫ 10 5 cells were suspended in 100 l of maintenance medium (Iscove's medium for K562 cells or Advanced RPMI medium 1640 for other cells, all supplemented with 2% FBS).…”

Section: Methodsmentioning

confidence: 99%

“…DENV-infected cells were transferred to an Eppendorf (Westbury, NY) tube and centrifuged to remove the supernatant. Fixation, permeabilization, and intracellular fluorescence labeling were performed essentially as described (34 Sequence Detection System. DENV-4 strain 814669 was used to generate a standard curve with 10-fold dilutions of RNA isolated from a known amount of virus (6.3 log 10 FFU/ml), covering a 5 log 10 dynamic range (6.3 log 10 to 1.3 log 10 FFU/ml).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Monoclonal antibody-mediated enhancement of dengue virus infectionin vitroandin vivoand strategies for prevention

Goncalvez

Engle

Claire

et al. 2007

Proc. Natl. Acad. Sci. U.S.A.

341

292

View full text Add to dashboard Cite

antibody-dependent enhancement ͉ nonhuman primate model ͉ Fc mutations ͉ cross-reactive mAb T he four dengue virus (DENV) serotypes (DENV-1 to DENV-4) are the most important arthropod-borne flaviviruses in terms of morbidity and geographic distribution. Up to 100 million DENV infections occur every year, mostly in tropical and subtropical areas where vector mosquitoes are abundant (1). Infection with any of the DENV serotypes may be asymptomatic or may lead to classic dengue fever or more severe dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), which are increasingly common in the dengue endemic areas. Immunity to the same virus serotype (homotypic immunity) is life-long, whereas immunity to different serotypes (heterotypic immunity) lasts 2-3 months so that infection with a different serotype virus is possible (2). DHF/DSS often occurs in patients with second, heterotypic DENV infections or in infants with maternally transferred dengue immunity (3, 4). Severe dengue is a major cause of hospitalization, and fatality rates vary from Ͻ1% to 5% in children.Antibody-dependent enhancement (ADE) has been proposed as an underlying pathogenic mechanism of DHF/DSS (3). ADE occurs because preexisting subneutralizing antibodies and the infecting DENV form complexes that bind to Fc receptorbearing cells, leading to increased virus uptake and replication (4). ADE has been repeatedly demonstrated in vitro using dengue immune sera or monoclonal antibodies and cells of monocytic and recently, B lymphocytic lineages bearing Fc receptors (5-7). ADE of DENV-2 infection has also been demonstrated in monkeys infused with a human dengue immune serum (8).Infection with DENV or any other flavivirus induces broadly cross-reactive but weak or nonneutralizing antibodies (9, 10). These antibodies remain detectable for a long period and rise rapidly during a subsequent heterotypic infection as a result of an anamnestic response. A major subset of these cross-reactive antibodies is directed to immuno-dominant epitopes involving determinants mapped to the flavivirus-conserved fusion peptide in the envelope glycoprotein (E) (11-13). The functional activities of these cross-reactive antibodies are not well characterized.We have identified chimpanzee-human chimeric IgG1 mAbs capable of neutralizing or binding to one or more DENV serotypes (14, 15). Cross-reactive IgG 1A5 neutralizes DENV-1 and DENV-2 more efficiently than DENV-3 and DENV-4, and type-specific IgG 5H2 neutralizes DENV-4 at a high titer (14,15). Analysis of antigenic variants has localized the IgG 1A5 binding site to the conserved fusion peptide in E (11). Thus, IgG 1A5 shares many characteristics with the cross-reactive antibodies detected in flavivirus infections.We investigated the ability of IgG 1A5 to mediate enhancement of DENV replication in monocyte-derived cell lines and in juvenile rhesus monkeys after passive transfer. We also explored strategies to reduce ADE by mutational analysis of the key structures in the Fc of IgG 1A5. A 9-aa deletion at the N termin...

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Monoclonal antibody-mediated enhancement of dengue virus infectionin vitroandin vivoand strategies for prevention

Goncalvez

Engle

Claire

et al. 2007

Proc. Natl. Acad. Sci. U.S.A.

341

292

View full text Add to dashboard Cite

show abstract

“…While the mechanisms of these processes are still not understood in detail, these aspects are carefully taken into consideration in vaccine development to avoid such adverse effects. 73,74 In the case of T. cruzi, there is now a large body of evidence indicating that disease progression is due to parasite persistence, and autoimmune reactions are rather a consequence of cardiac tissue damage than the main mechanism driving disease progression. [75][76][77][78] Also, several independent pre-clinical vaccine studies such as those highlighted above have repeatedly shown that the induction of a strong cellular immune response allows for a reduction in parasite burden as well as in cardiac tissue inflammation, rather than exacerbation of disease (Tables 1 and 2).…”

Section: Perspectives and Challenges To T Cruzi Vaccine Developmentmentioning

confidence: 99%

Advances and challenges towards a vaccine against Chagas disease

Quijano-Hernández

Dumonteil

2011

Human Vaccines

View full text Add to dashboard Cite

“…7 Given the lack of effective tools for the primary prevention of dengue, there has been a major effort to develop safe and effective dengue vaccines as a tool to prevent this disease. [10][11][12][13][14] Several dengue vaccines are now in late stage development and will begin to move into large scale clinical trials. [15][16][17] Because dengue is endemic in Puerto Rico, it has been considered as a potential site for a dengue vaccine efficacy trial.…”

Section: Introductionmentioning

confidence: 99%

Assessing the interest to participate in a dengue vaccine efficacy trial among residents of Puerto Rico

Guerra

Rodríguez-Acosta

Soto-Gomez

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine

Cited by 55 publications

References 20 publications

Monoclonal antibody-mediated enhancement of dengue virus infectionin vitroandin vivoand strategies for prevention

Monoclonal antibody-mediated enhancement of dengue virus infectionin vitroandin vivoand strategies for prevention

Advances and challenges towards a vaccine against Chagas disease

Assessing the interest to participate in a dengue vaccine efficacy trial among residents of Puerto Rico

Contact Info

Product

Resources

About